1
|
Al-Matarneh CM, Pinteala M, Nicolescu A, Silion M, Mocci F, Puf R, Angeli A, Ferraroni M, Supuran CT, Zara S, Carradori S, Paoletti N, Bonardi A, Gratteri P. Synthetic Approaches to Novel Human Carbonic Anhydrase Isoform Inhibitors Based on Pyrrol-2-one Moiety. J Med Chem 2024; 67:3018-3038. [PMID: 38301036 PMCID: PMC10895679 DOI: 10.1021/acs.jmedchem.3c02190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Revised: 01/10/2024] [Accepted: 01/11/2024] [Indexed: 02/03/2024]
Abstract
New dihydro-pyrrol-2-one compounds, featuring dual sulfonamide groups, were synthesized through a one-pot, three-component approach utilizing trifluoroacetic acid as a catalyst. Computational analysis using density functional theory (DFT) and condensed Fukui function explored the structure-reactivity relationship. Evaluation against human carbonic anhydrase isoforms (hCA I, II, IX, XII) revealed potent inhibition. The widely expressed cytosolic hCA I was inhibited across a range of concentrations (KI 3.9-870.9 nM). hCA II, also cytosolic, exhibited good inhibition as well. Notably, all compounds effectively inhibited tumor-associated hCA IX (KI 1.9-211.2 nM) and hCA XII (low nanomolar). Biological assessments on MCF7 cancer cells highlighted the compounds' ability, in conjunction with doxorubicin, to significantly impact tumor cell viability. These findings underscore the potential therapeutic relevance of the synthesized compounds in cancer treatment.
Collapse
Affiliation(s)
- Cristina M. Al-Matarneh
- Center
of Advanced Research in Bionanoconjugates and Biopolymers, “Petru Poni” Institute of Macromolecular
Chemistry of Romanian Academy, 41A Grigore Ghica Voda Alley, Iasi 700487, Romania
- Research
Institute of the University of Bucharest-ICUB, 90 Sos. Panduri, 050663 Bucharest, Romania
| | - Mariana Pinteala
- Center
of Advanced Research in Bionanoconjugates and Biopolymers, “Petru Poni” Institute of Macromolecular
Chemistry of Romanian Academy, 41A Grigore Ghica Voda Alley, Iasi 700487, Romania
| | - Alina Nicolescu
- NMR
Laboratory ”Petru Poni” Institute of Macromolecular
Chemistry of Romanian Academy, 41A Grigore Ghica Voda Alley, Iasi 700487, Romania
| | - Mihaela Silion
- Physics
of Polymers and Polymeric Materials Department, “Petru Poni” Institute of Macromolecular Chemistry, 41A Grigore Ghica Voda Alley, 700487 Iasi, Romania
| | - Francesca Mocci
- Department
of Chemical and Geological Sciences, University
of Cagliari, 09124 Cagliari, Italy
| | - Razvan Puf
- Center
of Advanced Research in Bionanoconjugates and Biopolymers, “Petru Poni” Institute of Macromolecular
Chemistry of Romanian Academy, 41A Grigore Ghica Voda Alley, Iasi 700487, Romania
| | - Andrea Angeli
- Sezione di
Scienze Farmaceutiche, NeuroFarba Department, Universita degli Studi di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy
| | - Marta Ferraroni
- Dipartimento
di Chimica “Ugo Schiff”, University
of Florence, Via della Lastruccia 3, 50019 Sesto Fiorentino, Florence Italy
| | - Claudiu T. Supuran
- Sezione di
Scienze Farmaceutiche, NeuroFarba Department, Universita degli Studi di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy
| | - Susi Zara
- Department
of Pharmacy, “G. d’Annunzio”
University of Chieti-Pescara, via dei Vestini 31, 66100 Chieti, Italy
| | - Simone Carradori
- Department
of Pharmacy, “G. d’Annunzio”
University of Chieti-Pescara, via dei Vestini 31, 66100 Chieti, Italy
| | - Niccolò Paoletti
- Department
of Chemical and Geological Sciences, University
of Cagliari, 09124 Cagliari, Italy
- Sezione di
Scienze Farmaceutiche, NeuroFarba Department, Universita degli Studi di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy
| | - Alessandro Bonardi
- Sezione di
Scienze Farmaceutiche, NeuroFarba Department, Universita degli Studi di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy
- NEUROFARBA
Department, Pharmaceutical and Nutraceutical Section, Laboratory of
Molecular Modeling Cheminformatics & QSAR, University of Florence, Via U. Schiff 6, 50019 Sesto Fiorentino, Firenze Italy
| | - Paola Gratteri
- NEUROFARBA
Department, Pharmaceutical and Nutraceutical Section, Laboratory of
Molecular Modeling Cheminformatics & QSAR, University of Florence, Via U. Schiff 6, 50019 Sesto Fiorentino, Firenze Italy
| |
Collapse
|
2
|
Al-Matarneh CM, Nicolescu A, Marinas IC, Chifiriuc MC, Shova S, Silion M, Pinteala M. Novel antimicrobial iodo-dihydro-pyrrole-2-one compounds. Future Med Chem 2023; 15:1369-1391. [PMID: 37577781 DOI: 10.4155/fmc-2023-0121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/15/2023] Open
Abstract
Aim: A series of new hybrid molecules with two iodine atoms on the sides were synthesized. Methods: A one-pot, two-component method with trifluoroacetic acid as an effective catalyst to obtain dihydro-pyrrol-2-one compounds was developed. Short reaction times, a cheap catalyst, high yields and clean work-up are benefits of this method. Results: The chemical structures of the newly synthesized compounds were verified through spectroscopic techniques. Their antimicrobial activity against Staphylococcus aureus, Pseudomonas aeruginosa and Candida albicans was tested in vitro. Conclusion: NC- and OH- radicals confer broad-spectrum antimicrobial activity, including against Gram-positive and Gram-negative bacteria and yeasts. Compounds 3g >7 and >9 were most active on the two bacterial species, while 3l >9 and >3i were most active against the fungal strain.
Collapse
Affiliation(s)
- Cristina M Al-Matarneh
- Research Institute of the University of Bucharest-ICUB, 91-95 Spl. Independentei, Bucharest, 050095, Romania
- Center of Advanced Research in Bionanoconjugates & Biopolymers, "Petru Poni" Institute of Macromolecular Chemistry of Romanian Academy, 41A Grigore Ghica Voda Alley, Iasi, 700487, Romania
| | - Alina Nicolescu
- NMR Laboratory "Petru Poni" Institute of Macromolecular Chemistry of Romanian Academy, 41A Grigore Ghica Voda Alley, Iasi, 700487, Romania
| | - Ioana C Marinas
- Research Institute of the University of Bucharest-ICUB, 91-95 Spl. Independentei, Bucharest, 050095, Romania
| | - Mariana C Chifiriuc
- Research Institute of the University of Bucharest-ICUB, 91-95 Spl. Independentei, Bucharest, 050095, Romania
| | - Sergiu Shova
- Department of Inorganic Polymers "Petru Poni" Institute of Macromolecular Chemistry of Romanian Academy, 41A Grigore Ghica Voda Alley, Iasi, 700487, Romania
| | - Mihaela Silion
- Physics of Polymers & Polymeric Materials Department, "Petru Poni" Institute of Macromolecular Chemistry, 41A Grigore Ghica Voda Alley, Iasi, 700487, Romania
| | - Mariana Pinteala
- Center of Advanced Research in Bionanoconjugates & Biopolymers, "Petru Poni" Institute of Macromolecular Chemistry of Romanian Academy, 41A Grigore Ghica Voda Alley, Iasi, 700487, Romania
| |
Collapse
|
3
|
New thiadiazole modified chitosan derivative to control the growth of human pathogenic microbes and cancer cell lines. Sci Rep 2022; 12:21423. [PMID: 36503959 PMCID: PMC9742148 DOI: 10.1038/s41598-022-25772-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2022] [Accepted: 12/05/2022] [Indexed: 12/14/2022] Open
Abstract
The emergence of multidrug-resistant microbes and the propagation of cancer cells are global health issues. The unique properties of chitosan and its derivatives make it an important candidate for therapeutic applications. Herein, a new thiadiazole derivative, 4-((5-(butylthio)-1,3,4-thiadiazol-2-yl) amino)-4-oxo butanoic acid (BuTD-COOH) was synthesized and used to modify the chitosan through amide linkages, forming a new thiadiazole chitosan derivative (BuTD-CH). The formation of thiadiazole and the chitosan derivative was confirmed by FT-IR, 1H/13C-NMR, GC-MS, TGA, Elemental analysis, and XPS. The BuTD-CH showed a high antimicrobial effect against human pathogens Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis, Staphylococcus aureus, and Candida albicans with low MIC values of 25-50 μg ml-1 compared to unmodified chitosan. The in-vitro cytotoxicity of BuTD-CH was evaluated against two cancer cell lines (MCF-7 and HepG2) and one normal cell (HFB4) using the MTT method. The newly synthesized derivatives showed high efficacy against cancerous cells and targeted them at low concentrations (IC50 was 178.9 ± 9.1 and 147.8 ± 10.5 μg ml-1 for MCF-7 and HepG2, respectively) compared with normal HFB4 cells (IC50 was 335.7 ± 11.4 μg ml-1). Thus, low concentrations of newly synthesized BuTD-CH could be safely used as an antimicrobial and pharmacological agent for inhibiting the growth of human pathogenic microbes and hepatocellular and adenocarcinoma therapy.
Collapse
|
4
|
Yang L, Liu Q, Liu H, Chen D, Li H, Chen Z, Xu W. Synthesis and antimicrobial bioassays of 1,3,4-thiadiazole sulfone derivatives containing amide moiety: A study based on molecular dynamics (MD) simulations, MM/GBSA, and molecular docking. JOURNAL OF SAUDI CHEMICAL SOCIETY 2022. [DOI: 10.1016/j.jscs.2021.101415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
5
|
Özil M, Tuzcuoğlu Ö, Emirik M, Baltaş N. Developing a scaffold for urease inhibition based on benzothiazoles: Synthesis, docking analysis, and therapeutic potential. Arch Pharm (Weinheim) 2021; 354:e2100200. [PMID: 34545964 DOI: 10.1002/ardp.202100200] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2021] [Revised: 09/01/2021] [Accepted: 09/04/2021] [Indexed: 12/31/2022]
Abstract
The synthesis, in silico molecular docking, and in vitro urease inhibition studies of a novel series of benzothiazole derivatives are reported. The title compounds in the two series, namely, 2-({5-[(benzothiazol-2-ylthio)methyl]-1,3,4-oxadiazol-2-yl}thio)-1-(4-substituted-phenyl)ethan-1-one and 2-(benzothiazol-2-ylthio)-1-(4-substituted-phenyl)ethan-1-one oxime, were synthesized by the reaction of benzo[d]thiazole-2-thiol with different kinds of intermediates in several steps using both conventional and microwave techniques. All compounds were found to have an excellent degree of urease-inhibitory potential ranging between 16.16 ± 0.54 and 105.32 ± 2.10 µM when compared with the standard inhibitor acetohydroxamic acid with IC50 = 320.70 ± 4.24 µM. The structure-activity relationship was established in detail. The binding interactions of the compounds with the enzyme were confirmed through molecular docking. Further, 100 -ns molecular dynamics simulations were performed to investigate the stability and structural perturbations experienced by the most potent compound over the urease active site.
Collapse
Affiliation(s)
- Musa Özil
- Department of Chemistry, Recep Tayyip Erdogan University, Rize, Turkey
| | - Özge Tuzcuoğlu
- Department of Chemistry, Recep Tayyip Erdogan University, Rize, Turkey
| | - Mustafa Emirik
- Department of Chemistry, Recep Tayyip Erdogan University, Rize, Turkey
| | - Nimet Baltaş
- Department of Chemistry, Recep Tayyip Erdogan University, Rize, Turkey
| |
Collapse
|
6
|
Voss S, Nitsche C. Targeting the protease of West Nile virus. RSC Med Chem 2021; 12:1262-1272. [PMID: 34458734 PMCID: PMC8372202 DOI: 10.1039/d1md00080b] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Accepted: 05/17/2021] [Indexed: 01/04/2023] Open
Abstract
West Nile virus infections can cause severe neurological symptoms. During the last 25 years, cases have been reported in Asia, North America, Africa, Europe and Australia (Kunjin). No West Nile virus vaccines or specific antiviral therapies are available to date. Various viral proteins and host-cell factors have been evaluated as potential drug targets. The viral protease NS2B-NS3 is among the most promising viral targets. It releases viral proteins from a non-functional polyprotein precursor, making it a critical factor of viral replication. Despite strong efforts, no protease inhibitors have reached clinical trials yet. Substrate-derived peptidomimetics have facilitated structural elucidations of the active protease state, while alternative compounds with increased drug-likeness have recently expanded drug discovery efforts beyond the active site.
Collapse
Affiliation(s)
- Saan Voss
- Research School of Chemistry, Australian National University Canberra ACT 2601 Australia
| | - Christoph Nitsche
- Research School of Chemistry, Australian National University Canberra ACT 2601 Australia
| |
Collapse
|
7
|
Sinigaglia A, Peta E, Riccetti S, Barzon L. New avenues for therapeutic discovery against West Nile virus. Expert Opin Drug Discov 2020; 15:333-348. [DOI: 10.1080/17460441.2020.1714586] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
| | - Elektra Peta
- Department of Molecular Medicine, University of Padova, Padova, Italy
| | - Silvia Riccetti
- Department of Molecular Medicine, University of Padova, Padova, Italy
| | - Luisa Barzon
- Department of Molecular Medicine, University of Padova, Padova, Italy
| |
Collapse
|
8
|
Kassem AF, Nassar IF, Abdel-Aal MT, Awad HM, El-Sayed WA. Synthesis and Anticancer Activity of New ((Furan-2-yl)-1,3,4-thiadiazolyl)-1,3,4-oxadiazole Acyclic Sugar Derivatives. Chem Pharm Bull (Tokyo) 2019; 67:888-895. [PMID: 31366838 DOI: 10.1248/cpb.c19-00280] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
New sugar hydrazones incorporating furan and/or 1,3,4-thiadiazole ring systems were synthesized by reaction of the corresponding hydrazide with different aldose sugars. Heterocyclization of the formed hydrazones afforded the derived acyclic nucleoside analogues possessing the 1,3,4-oxadiazoline as modified nucleobase via acetylation followed by the heterocyclization process. The anticancer activity of the synthesized compounds was studied against human liver carcinoma cell (HepG-2) and at human normal retina pigmented epithelium cells (RPE-1). High activities were revealed by compounds 3, 12 and 14 with IC50 values near to that of the reference drug doxorubicin.
Collapse
Affiliation(s)
- Asmaa F Kassem
- Chemistry of Natural and Microbial Products Department, National Research Centre
| | | | | | - Hanem M Awad
- Tanning Materials and Leather Technology Department, National Research Centre
| | - Wael A El-Sayed
- Chemistry Department, Faculty of Science, Qassim University.,Photochemistry Department, National Research Centre
| |
Collapse
|
9
|
Erdogan T. Ultrasound-assisted improved synthesis of 5-(benzylthio)-1,3,4-thiadiazol-2-amine derivatives: an experimental and computational study. JOURNAL OF THE IRANIAN CHEMICAL SOCIETY 2018. [DOI: 10.1007/s13738-018-1567-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
10
|
Abstract
The persistence of West Nile virus (WNV) infections throughout the USA since its inception in 1999 and its continuous spread throughout the globe calls for an urgent need of effective treatments and prevention measures. Although the licensing of several WNV vaccines for veterinary use provides a proof of concept, similar efforts on the development of an effective vaccine for humans remain still unsuccessful. Increased understanding of biology and pathogenesis of WNV together with recent technological advancements have raised hope that an effective WNV vaccine may be available in the near future. In addition, rapid progress in the structural and functional characterization of WNV and other flaviviral proteins have provided a solid base for the design and development of several classes of inhibitors as potential WNV therapeutics. Moreover, the therapeutic monoclonal antibodies demonstrate an excellent efficacy against WNV in animal models and represent a promising class of WNV therapeutics. However, there are some challenges as to the design and development of a safe and efficient WNV vaccine or therapeutic. In this chapter, we discuss the current approaches, progress, and challenges toward the development of WNV vaccines, therapeutic antibodies, and antiviral drugs.
Collapse
|
11
|
STD-NMR experiments identify a structural motif with novel second-site activity against West Nile virus NS2B-NS3 protease. Antiviral Res 2017; 146:174-183. [PMID: 28927677 DOI: 10.1016/j.antiviral.2017.09.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2017] [Revised: 09/09/2017] [Accepted: 09/14/2017] [Indexed: 11/22/2022]
Abstract
West Nile virus (WNV) belongs to the genus Flavivirus of the family Flaviviridae. This mosquito-borne virus that is highly pathogenic to humans has been evolving into a global threat during the past two decades. Despite many efforts, neither antiviral drugs nor vaccines are available. The viral protease NS2B-NS3pro is essential for viral replication, and therefore it is considered a prime drug target. However, success in the development of specific NS2B-NS3pro inhibitors had been moderate so far. In the search for new structural motifs with binding affinity for NS2B-NS3pro, we have screened a fragment library, the Maybridge Ro5 library, employing saturation transfer difference (STD) NMR experiments as readout. About 30% of 429 fragments showed binding to NS2B-NS3pro. Subsequent STD-NMR competition experiments using the known active site fragment A as reporter ligand yielded 14 competitively binding fragments, and 22 fragments not competing with A. In a fluorophore-based protease assay, all of these fragments showed inhibition in the micromolar range. Interestingly, 10 of these 22 fragments showed a notable increase of STD intensities in the presence of compound A suggesting cooperative binding. The most promising non-competitive inhibitors 1 and 2 (IC50 ∼ 500 μM) share a structural motif that may guide the development of novel second-site (potentially allosteric) inhibitors of NS2B-NS3pro. To identify the matching protein binding site, chemical shift perturbation studies employing 1H,15N-TROSY-HSQC experiments with uniformly 2H,15N-labeled protease were performed in the presence of 1, and in the concomitant absence or presence of A. The data suggest that 1 interacts with Met 52* of NS2B, identifying a secondary site adjacent to the binding site of A. Therefore, our study paves the way for the synthesis of novel bidentate NS2B-NS3pro inhibitors.
Collapse
|
12
|
Kouretova J, Hammamy MZ, Epp A, Hardes K, Kallis S, Zhang L, Hilgenfeld R, Bartenschlager R, Steinmetzer T. Effects of NS2B-NS3 protease and furin inhibition on West Nile and Dengue virus replication. J Enzyme Inhib Med Chem 2017; 32:712-721. [PMID: 28385094 PMCID: PMC6445162 DOI: 10.1080/14756366.2017.1306521] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
West Nile virus (WNV) and Dengue virus (DENV) replication depends on the viral NS2B-NS3 protease and the host enzyme furin, which emerged as potential drug targets. Modification of our previously described WNV protease inhibitors by basic phenylalanine analogs provided compounds with reduced potency against the WNV and DENV protease. In a second series, their decarboxylated P1-trans-(4-guanidino)cyclohexylamide was replaced by an arginyl-amide moiety. Compound 4-(guanidinomethyl)-phenylacetyl-Lys-Lys-Arg-NH2 inhibits the NS2B-NS3 protease of WNV with an inhibition constant of 0.11 µM. Due to the similarity in substrate specificity, we have also tested the potency of our previously described multibasic furin inhibitors. Their further modification provided chimeric inhibitors with additional potency against the WNV and DENV proteases. A strong inhibition of WNV and DENV replication in cell culture was observed for the specific furin inhibitors, which reduced virus titers up to 10,000-fold. These studies reveal that potent inhibitors of furin can block the replication of DENV and WNV.
Collapse
Affiliation(s)
- Jenny Kouretova
- a Department of Pharmacy, Institute of Pharmaceutical Chemistry , Philipps University , Marburg , Germany.,b German Center for Infection Research (DZIF) , University of Marburg , Marburg , Germany
| | - M Zouhir Hammamy
- a Department of Pharmacy, Institute of Pharmaceutical Chemistry , Philipps University , Marburg , Germany
| | - Anton Epp
- a Department of Pharmacy, Institute of Pharmaceutical Chemistry , Philipps University , Marburg , Germany
| | - Kornelia Hardes
- a Department of Pharmacy, Institute of Pharmaceutical Chemistry , Philipps University , Marburg , Germany
| | - Stephanie Kallis
- c Department of Infectious Diseases, Molecular Virology , Heidelberg University , Heidelberg , Germany
| | - Linlin Zhang
- d Institute of Biochemistry, Center for Structural and Cell Biology in Medicine, University of Lübeck , Lübeck , Germany.,e German Center for Infection Research (DZIF) , University of Lübeck , Lübeck , Germany
| | - Rolf Hilgenfeld
- d Institute of Biochemistry, Center for Structural and Cell Biology in Medicine, University of Lübeck , Lübeck , Germany.,e German Center for Infection Research (DZIF) , University of Lübeck , Lübeck , Germany
| | - Ralf Bartenschlager
- c Department of Infectious Diseases, Molecular Virology , Heidelberg University , Heidelberg , Germany.,f German Center for Infection Research (DZIF) , Heidelberg University , Heidelberg , Germany
| | - Torsten Steinmetzer
- a Department of Pharmacy, Institute of Pharmaceutical Chemistry , Philipps University , Marburg , Germany.,b German Center for Infection Research (DZIF) , University of Marburg , Marburg , Germany
| |
Collapse
|
13
|
Vernekar SKV, Qiu L, Zhang J, Kankanala J, Li H, Geraghty RJ, Wang Z. 5'-Silylated 3'-1,2,3-triazolyl Thymidine Analogues as Inhibitors of West Nile Virus and Dengue Virus. J Med Chem 2015; 58:4016-28. [PMID: 25909386 DOI: 10.1021/acs.jmedchem.5b00327] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
West Nile virus (WNV) and Dengue virus (DENV) are important human pathogens for which there are presently no vaccine or specific antivirals. We report herein a 5'-silylated nucleoside scaffold derived from 3'-azidothymidine (AZT) consistently and selectively inhibiting WNV and DENV at low micromolar concentrations. Further synthesis of various triazole bioisosteres demonstrated clear structure-activity relationships (SARs) in which the antiviral activity against WNV and DENV hinges largely on both the 5'-silyl group and the substituent of 3'-triazole or its bioisosteres. Particularly interesting is the 5' silyl group which turns on the antiviral activity against WNV and DENV while abrogating the previously reported antiviral potency against human immunodeficiency virus (HIV-1). The antiviral activity was confirmed through a plaque assay where viral titer reduction was observed in the presence of selected compounds. Molecular modeling and competitive S-adenosyl-l-methionine (SAM) binding assay suggest that these compounds likely confer antiviral activity via binding to methyltransferase (MTase).
Collapse
Affiliation(s)
- Sanjeev Kumar V Vernekar
- †Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Li Qiu
- †Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Jing Zhang
- ‡Wadsworth Center, New York State Department of Health, 120 New Scotland Ave., Albany, New York 12208, United States
| | - Jayakanth Kankanala
- †Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Hongmin Li
- ‡Wadsworth Center, New York State Department of Health, 120 New Scotland Ave., Albany, New York 12208, United States.,§Department of Biomedical Sciences, School of Public Health, University at Albany, Albany, New York 12201, United States
| | - Robert J Geraghty
- †Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, Minnesota 55455, United States
| | - Zhengqiang Wang
- †Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, Minnesota 55455, United States
| |
Collapse
|
14
|
Pelkey ET, Pelkey SJ, Greger JG. De Novo Synthesis of 3-Pyrrolin-2-Ones. ADVANCES IN HETEROCYCLIC CHEMISTRY 2015. [DOI: 10.1016/bs.aihch.2015.04.001] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
15
|
Bhakat S, Karubiu W, Jayaprakash V, Soliman ME. A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, West Nile and Chikungunya viruses. Eur J Med Chem 2014; 87:677-702. [DOI: 10.1016/j.ejmech.2014.10.010] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2014] [Revised: 09/29/2014] [Accepted: 10/04/2014] [Indexed: 01/07/2023]
|
16
|
Recent Advances in Targeting Dengue and West Nile Virus Proteases Using Small Molecule Inhibitors. TOPICS IN MEDICINAL CHEMISTRY 2014. [DOI: 10.1007/7355_2014_46] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
17
|
Lim SP, Shi PY. West Nile virus drug discovery. Viruses 2013; 5:2977-3006. [PMID: 24300672 PMCID: PMC3967157 DOI: 10.3390/v5122977] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2013] [Revised: 11/25/2013] [Accepted: 11/25/2013] [Indexed: 02/08/2023] Open
Abstract
The outbreak of West Nile virus (WNV) in 1999 in the USA, and its continued spread throughout the Americas, parts of Europe, the Middle East and Africa, underscored the need for WNV antiviral development. Here, we review the current status of WNV drug discovery. A number of approaches have been used to search for inhibitors of WNV, including viral infection-based screening, enzyme-based screening, structure-based virtual screening, structure-based rationale design, and antibody-based therapy. These efforts have yielded inhibitors of viral or cellular factors that are critical for viral replication. For small molecule inhibitors, no promising preclinical candidate has been developed; most of the inhibitors could not even be advanced to the stage of hit-to-lead optimization due to their poor drug-like properties. However, several inhibitors developed for related members of the family Flaviviridae, such as dengue virus and hepatitis C virus, exhibited cross-inhibition of WNV, suggesting the possibility to re-purpose these antivirals for WNV treatment. Most promisingly, therapeutic antibodies have shown excellent efficacy in mouse model; one of such antibodies has been advanced into clinical trial. The knowledge accumulated during the past fifteen years has provided better rationale for the ongoing WNV and other flavivirus antiviral development.
Collapse
Affiliation(s)
- Siew Pheng Lim
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, Chromos 05-01, Singapore 138670, Singapore.
| | | |
Collapse
|
18
|
The flavivirus protease as a target for drug discovery. Virol Sin 2013; 28:326-36. [PMID: 24242363 DOI: 10.1007/s12250-013-3390-x] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2013] [Accepted: 11/01/2013] [Indexed: 01/27/2023] Open
Abstract
Many flaviviruses are significant human pathogens causing considerable disease burdens, including encephalitis and hemorrhagic fever, in the regions in which they are endemic. A paucity of treatments for flaviviral infections has driven interest in drug development targeting proteins essential to flavivirus replication, such as the viral protease. During viral replication, the flavivirus genome is translated as a single polyprotein precursor, which must be cleaved into individual proteins by a complex of the viral protease, NS3, and its cofactor, NS2B. Because this cleavage is an obligate step of the viral life-cycle, the flavivirus protease is an attractive target for antiviral drug development. In this review, we will survey recent drug development studies targeting the NS3 active site, as well as studies targeting an NS2B/NS3 interaction site determined from flavivirus protease crystal structures.
Collapse
|